Kathleen E Delgiorno1, Jason C Hall2, Kenneth K Takeuchi3, Fong Cheng Pan4, Christopher J Halbrook2, M Kay Washington5, Kenneth P Olive6, Jason R Spence7, Bence Sipos8, Christopher V E Wright4, James M Wells9, Howard C Crawford10. 1. Department of Molecular Genetics and Microbiology, Stony Brook University, Stony Brook, New York; Department of Cancer Biology, Mayo Clinic, Jacksonville, Florida. 2. Department of Cancer Biology, Mayo Clinic, Jacksonville, Florida; Department of Pharmacological Sciences, Stony Brook University, Stony Brook, New York. 3. Department of Cancer Biology, Mayo Clinic, Jacksonville, Florida. 4. Department of Cell and Developmental Biology, Vanderbilt University Medical Center, Nashville, Tennessee. 5. Department of Pathology, Vanderbilt University Medical Center, Nashville, Tennessee. 6. Departments of Medicine and Pathology, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, New York. 7. Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan. 8. Department of Pathology, University Hospital Tubingen, Tubingen, Germany. 9. Department of Developmental Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio. 10. Department of Molecular Genetics and Microbiology, Stony Brook University, Stony Brook, New York; Department of Cancer Biology, Mayo Clinic, Jacksonville, Florida. Electronic address: crawford.howard@mayo.edu.
Abstract
BACKGROUND & AIMS: Metaplasias often have characteristics of developmentally related tissues. Pancreatic metaplastic ducts are usually associated with pancreatitis and pancreatic ductal adenocarcinoma. The tuft cell is a chemosensory cell that responds to signals in the extracellular environment via effector molecules. Commonly found in the biliary tract, tuft cells are absent from normal murine pancreas. Using the aberrant appearance of tuft cells as an indicator, we tested if pancreatic metaplasia represents transdifferentiation to a biliary phenotype and what effect this has on pancreatic tumorigenesis. METHODS: We analyzed pancreatic tissue and tumors that developed in mice that express an activated form of Kras (Kras(LSL-G12D/+);Ptf1a(Cre/+) mice). Normal bile duct, pancreatic duct, and tumor-associated metaplasias from the mice were analyzed for tuft cell and biliary progenitor markers, including SOX17, a transcription factor that regulates biliary development. We also analyzed pancreatic tissues from mice expressing transgenic SOX17 alone (ROSA(tTa/+);Ptf1(CreERTM/+);tetO-SOX17) or along with activated Kras (ROSAtT(a/+);Ptf1a(CreERTM/+);tetO-SOX17;Kras(LSL-G12D;+)). RESULTS: Tuft cells were frequently found in areas of pancreatic metaplasia, decreased throughout tumor progression, and absent from invasive tumors. Analysis of the pancreatobiliary ductal systems of mice revealed tuft cells in the biliary tract but not the normal pancreatic duct. Analysis for biliary markers revealed expression of SOX17 in pancreatic metaplasia and tumors. Pancreas-specific overexpression of SOX17 led to ductal metaplasia along with inflammation and collagen deposition. Mice that overexpressed SOX17 along with Kras(G12D) had a greater degree of transformed tissue compared with mice expressing only Kras(G12D). Immunofluorescence analysis of human pancreatic tissue arrays revealed the presence of tuft cells in metaplasia and early-stage tumors, along with SOX17 expression, consistent with a biliary phenotype. CONCLUSIONS: Expression of Kras(G12D) and SOX17 in mice induces development of metaplasias with a biliary phenotype containing tuft cells. Tuft cells express a number of tumorigenic factors that can alter the microenvironment. Expression of SOX17 induces pancreatitis and promotes Kras(G12D)-induced tumorigenesis in mice.
BACKGROUND & AIMS:Metaplasias often have characteristics of developmentally related tissues. Pancreatic metaplastic ducts are usually associated with pancreatitis and pancreatic ductal adenocarcinoma. The tuft cell is a chemosensory cell that responds to signals in the extracellular environment via effector molecules. Commonly found in the biliary tract, tuft cells are absent from normal murine pancreas. Using the aberrant appearance of tuft cells as an indicator, we tested if pancreatic metaplasia represents transdifferentiation to a biliary phenotype and what effect this has on pancreatic tumorigenesis. METHODS: We analyzed pancreatic tissue and tumors that developed in mice that express an activated form of Kras (Kras(LSL-G12D/+);Ptf1a(Cre/+) mice). Normal bile duct, pancreatic duct, and tumor-associated metaplasias from the mice were analyzed for tuft cell and biliary progenitor markers, including SOX17, a transcription factor that regulates biliary development. We also analyzed pancreatic tissues from mice expressing transgenicSOX17 alone (ROSA(tTa/+);Ptf1(CreERTM/+);tetO-SOX17) or along with activated Kras (ROSAtT(a/+);Ptf1a(CreERTM/+);tetO-SOX17;Kras(LSL-G12D;+)). RESULTS: Tuft cells were frequently found in areas of pancreatic metaplasia, decreased throughout tumor progression, and absent from invasive tumors. Analysis of the pancreatobiliary ductal systems of mice revealed tuft cells in the biliary tract but not the normal pancreatic duct. Analysis for biliary markers revealed expression of SOX17 in pancreatic metaplasia and tumors. Pancreas-specific overexpression of SOX17 led to ductal metaplasia along with inflammation and collagen deposition. Mice that overexpressed SOX17 along with Kras(G12D) had a greater degree of transformed tissue compared with mice expressing only Kras(G12D). Immunofluorescence analysis of humanpancreatic tissue arrays revealed the presence of tuft cells in metaplasia and early-stage tumors, along with SOX17 expression, consistent with a biliary phenotype. CONCLUSIONS: Expression of Kras(G12D) and SOX17 in mice induces development of metaplasias with a biliary phenotype containing tuft cells. Tuft cells express a number of tumorigenic factors that can alter the microenvironment. Expression of SOX17 induces pancreatitis and promotes Kras(G12D)-induced tumorigenesis in mice.
Authors: Oliver Strobel; David E Rosow; Elena Y Rakhlin; Gregory Y Lauwers; Amanda G Trainor; Janivette Alsina; Carlos Fernández-Del Castillo; Andrew L Warshaw; Sarah P Thayer Journal: Gastroenterology Date: 2009-12-21 Impact factor: 22.682
Authors: Alexei V Salnikov; Ariane Groth; Anja Apel; Georgios Kallifatidis; Benjamin M Beckermann; Akmal Khamidjanov; Eduard Ryschich; Markus W Büchler; Ingrid Herr; Gerhard Moldenhauer Journal: J Cell Mol Med Date: 2009-09 Impact factor: 5.310
Authors: C Benedikt Westphalen; Yoshihiro Takemoto; Takayuki Tanaka; Marina Macchini; Zhengyu Jiang; Bernhard W Renz; Xiaowei Chen; Steffen Ormanns; Karan Nagar; Yagnesh Tailor; Randal May; Youngjin Cho; Samuel Asfaha; Daniel L Worthley; Yoku Hayakawa; Aleksandra M Urbanska; Michael Quante; Maximilian Reichert; Joshua Broyde; Prem S Subramaniam; Helen Remotti; Gloria H Su; Anil K Rustgi; Richard A Friedman; Barry Honig; Andrea Califano; Courtney W Houchen; Kenneth P Olive; Timothy C Wang Journal: Cell Stem Cell Date: 2016-04-07 Impact factor: 24.633
Authors: Moritz Middelhoff; C Benedikt Westphalen; Yoku Hayakawa; Kelley S Yan; Michael D Gershon; Timothy C Wang; Michael Quante Journal: Am J Physiol Gastrointest Liver Physiol Date: 2017-07-06 Impact factor: 4.052
Authors: Raphael Schellnegger; Anne Quante; Susanne Rospleszcz; Martina Schernhammer; Bettina Höhl; Moritz Tobiasch; Agnieszka Pastula; Anna Brandtner; Julian A Abrams; Konstantin Strauch; Roland M Schmid; Michael Vieth; Timothy C Wang; Michael Quante Journal: Cancer Prev Res (Phila) Date: 2016-11-02